Replimune (REPL) Non-Current Assets (2018 - 2025)
Replimune's (REPL) quarterly Non-Current Assets came in at $53.2 million in Q4 2025, down 5.02% year-on-year from $56.1 million in Q4 2024, and down 4.43% quarter-over-quarter from $55.7 million in Q3 2025.
Replimune (REPL) Non-Current Assets (2018 - 2025) Analysis & Trends
Replimune has disclosed Non-Current Assets across 8 years of filings, most recently posting $53.2 million for Q4 2025.
- Non-Current Assets for Q4 2025 came in at $53.2 million, down 5.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $220.5 million (changed 0.09% YoY), and the FY2025 annual result was $55.4 million, up 2.58% from the prior year.
- Non-Current Assets came in at $53.2 million for Q4 2025 at Replimune, down from $55.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $59.4 million in Q1 2021 to a low of $53.2 million in Q4 2025.
- The 5-year median for Non-Current Assets is $55.6 million (2024), against an average of $55.9 million.
- Across the five-year window, Non-Current Assets decreased 6.32% in 2023 and rose 4.25% in 2024, its largest moves.
- Replimune's Non-Current Assets stood at $57.5 million in 2021, then slipped by 5.04% to $54.6 million in 2022, then declined by 1.51% to $53.8 million in 2023, then increased by 4.25% to $56.1 million in 2024, then fell by 5.02% to $53.2 million in 2025.
- The last three Non-Current Assets figures came in at $53.2 million (Q4 2025), $55.7 million (Q3 2025), and $56.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 53.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.24 Mn |
| Sep 30, 2025 | 55.70 Mn |
| Jun 30, 2025 | 56.14 Mn |
| Mar 31, 2025 | 55.45 Mn |
| Dec 31, 2024 | 56.05 Mn |
| Sep 30, 2024 | 55.57 Mn |
| Jun 30, 2024 | 54.65 Mn |
| Mar 31, 2024 | 54.06 Mn |
| Dec 31, 2023 | 53.77 Mn |
| Sep 30, 2023 | 54.22 Mn |
| Jun 30, 2023 | 53.85 Mn |
| Mar 31, 2023 | 53.99 Mn |
| Dec 31, 2022 | 54.59 Mn |
| Sep 30, 2022 | 56.71 Mn |
| Jun 30, 2022 | 57.48 Mn |
| Mar 31, 2022 | 57.22 Mn |
| Dec 31, 2021 | 57.49 Mn |
| Sep 30, 2021 | 59.08 Mn |
| Jun 30, 2021 | 59.16 Mn |
| Mar 31, 2021 | 59.35 Mn |